Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells

Biochemistry, Genetics and Molecular Biology

• Antineoplastic Activity 9%
• Apoptosis 45%
• Autophosphorylation 9%
• Bcl-2 9%
• Cancer Cell 9%
• Cell Count 9%
• Cell Cycle 9%
• Degradation 9%
• Dose 9%
• Epidermal Growth Factor Receptor 27%
• G1 Phase 9%
• Gefitinib 100%
• Growth Inhibition 18%
• Human 9%
• Length 9%
• Messenger RNA 9%
• P21 18%
• P53 9%
• Receptor Tyrosine Kinase 9%
• Receptor Tyrosine Kinase Inhibitors 9%
• RNA 9%
• Serine 9%
• Signal Transduction 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Adenocarcinoma 18%
• Apoptosis 45%
• Cell Cycle 9%
• Double Stranded RNA 9%
• Epidermal Growth Factor Receptor 18%
• Epidermal Growth Factor Receptor Kinase Inhibitor 9%
• Gefitinib 100%
• Human 9%
• Malignant Neoplasm 9%
• Messenger RNA 9%
• Neoplasm 9%
• Protein P53 9%
• Serine 9%